Predictors of clomiphene citrate response in men with testosterone deficiency

If you have been told your testosterone is low and someone has already mentioned injections or gels, clomiphene citrate probably did not come up. That is not unusual. Clomiphene -- often called Clomid, though that brand name is most associated with female fertility treatment -- is one of the more underused options in male hypogonadism, partly because of a knowledge gap and partly because it does not fit the quick-script model many low-T clinics run on.

But the evidence for clomiphene in the right man is real. A 2025 study published in Andrology looked specifically at which men respond best to clomiphene, and the findings matter if you are trying to make a genuinely informed decision about your own care (https://pubmed.ncbi.nlm.nih.gov/42251758/). At NoMi Beach Health, we include clomiphene in the conversation when the workup supports it -- and that conversation starts long before we write anything.

Why the distinction between primary and secondary hypogonadism changes everything

Testosterone deficiency has two broad origins, and they require completely different thinking.

In primary hypogonadism, the problem lives in the testes themselves. They are not producing enough testosterone even when the brain is sending the right signals. Lab work shows low testosterone alongside high or inappropriately normal LH and FSH -- the brain is shouting, the testes are not answering. This pattern often follows injury, infection, chemotherapy, or is genetic (Klinefelter syndrome being the classic example).

In secondary hypogonadism, the testes are capable of producing testosterone but the signaling from the brain is too weak. LH and FSH are low or low-normal alongside low testosterone. The testes are quiet because they have not been told to work, not because they cannot. This pattern commonly follows obesity, obstructive sleep apnea, chronic opioid use, pituitary dysfunction, and sometimes no clear identifiable cause.

Clomiphene works upstream. It blocks estrogen receptors in the hypothalamus, which tricks the brain into sensing less estrogen and releasing more GnRH. That triggers more LH and FSH from the pituitary, which tells the testes to produce more testosterone. If the testes can still respond -- which they can in secondary hypogonadism -- testosterone rises. If the testes cannot respond -- as in primary hypogonadism -- clomiphene cannot help much, because the signal arrives and nothing happens.

This is not nuance for its own sake. It is the foundational question that separates men who are good candidates for clomiphene from men who are not.

What the 2025 data on predictors of response actually show

The Ramasamy group's 2025 analysis in Andrology (https://pubmed.ncbi.nlm.nih.gov/42251758/) examined predictors of clomiphene response in a real-world cohort of men with confirmed testosterone deficiency. Several findings stand out for anyone making clinical decisions.

Baseline LH level was among the strongest predictors. Men with lower baseline LH -- the pattern consistent with secondary hypogonadism -- were significantly more likely to achieve a meaningful testosterone response. This supports what the mechanistic model would predict: clomiphene is most useful when the axis is intact but understimulated.

Age mattered as well. Younger men tended to respond more robustly, likely because testicular reserve -- the capacity of the Leydig cells to ramp up production -- diminishes with age. This does not mean clomiphene is useless in older men, but the expectation should be calibrated accordingly.

Baseline testosterone level and estradiol-to-testosterone ratio also had predictive value. Men with moderately suppressed testosterone (as opposed to severely suppressed levels) tended to do better, consistent with the idea that there is still a partially functioning axis to stimulate.

What this means practically: a man in his 30s with a total testosterone of 240 ng/dL, a low-normal LH of 2.1 mIU/mL, and no history of testicular damage is a very different candidate than a man in his 55s with the same testosterone level, an LH of 12 mIU/mL, and a history of orchitis. The first man has a reasonable shot at responding to clomiphene. The second man almost certainly does not, and should be offered a different path.

How this fits into what we already know about clomiphene safety and long-term use

The 2025 predictor data builds on a longer track record. A study published in BJU International by Moskovic and colleagues followed men on clomiphene for up to three years and found sustained testosterone elevation with an acceptable safety profile (https://pubmed.ncbi.nlm.nih.gov/22220975/). Shabsigh and colleagues demonstrated that clomiphene raises the testosterone-to-estradiol ratio in ways that correlate with symptom improvement (https://pubmed.ncbi.nlm.nih.gov/16422870/).

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy acknowledges clomiphene as an off-label option for men who want to preserve fertility (https://pubmed.ncbi.nlm.nih.gov/29562364/), and the AUA's testosterone deficiency guideline similarly recognizes it in this context (https://pubmed.ncbi.nlm.nih.gov/29601923/). "Off-label" here does not mean experimental -- it means FDA approval was never sought for this specific indication, not that the evidence is absent.

The most common issue we monitor for is estradiol elevation. More testosterone means more substrate for aromatization to estrogen, and some men convert aggressively. Symptoms can include mood shifts and, in some cases, breast tenderness. We check estradiol at baseline, at 6 to 8 weeks, and at 3 months. If estradiol rises disproportionately, we adjust the plan -- sometimes with an aromatase inhibitor, sometimes by reconsidering the approach altogether.

Visual disturbances are the rare but serious signal that warrants stopping clomiphene immediately. Men should know this before starting.

The fertility conversation you should have before choosing TRT

This is the part of the low-testosterone discussion that gets skipped most often, and it should not be.

Conventional TRT -- injections, gels, pellets -- suppresses the hypothalamic-pituitary-gonadal axis. LH and FSH fall. Sperm production drops, sometimes to zero. In most men this is reversible after stopping TRT, but recovery is not guaranteed and can take 6 to 18 months or longer. For men who have not yet had children or who are not certain they are done, that is a significant consideration.

Clomiphene does the opposite. Because it stimulates endogenous production, LH and FSH rise, and sperm production is maintained or improved. For a man with secondary hypogonadism who is 34, symptomatic, and has not ruled out children, clomiphene is not just an alternative to TRT -- it may be the better first move on evidence.

We ask about fertility at each initial testosterone visit. Not as a checkbox, but because the answer changes what we recommend. If you are on TRT and no one has ever asked, that is worth noting. Our post on understanding testosterone replacement therapy covers the fertility suppression issue in more detail.

What our evaluation looks like before we make a recommendation

We do not start with a treatment. We start with a workup.

Two morning testosterone draws are standard -- the AUA guideline requires two below 300 ng/dL before a diagnosis is confirmed (https://pubmed.ncbi.nlm.nih.gov/29601923/). Afternoon draws are systematically lower and should not drive a diagnosis. Alongside total testosterone, we draw LH, FSH, estradiol, SHBG, prolactin, complete metabolic panel, CBC, and thyroid function. If clinical signs suggest it, we add a pituitary MRI.

The LH and FSH pattern is the hinge. Low-normal LH with low testosterone points toward secondary hypogonadism and opens the door to clomiphene. Elevated LH with low testosterone tells us the testes are the problem and closes it.

We also look for reversible causes before we do anything. Untreated sleep apnea is one of the most common and most ignored drivers of secondary hypogonadism. Obesity, hypothyroidism, elevated prolactin, and chronic opioid use all suppress testosterone through central mechanisms. We address those first. If testosterone normalizes with weight loss or sleep apnea treatment, a man has avoided a medication he did not need.

If clomiphene is appropriate, we start at a low dose, recheck labs at 6 to 8 weeks, and assess symptom trajectory at 3 months. We follow signs of low testosterone throughout, because lab improvement without symptom improvement is an incomplete response.

For men whose workup points more clearly to TRT as the better option -- primary hypogonadism, no fertility goals, poor clomiphene candidacy -- we follow that path instead. That decision-making framework is covered in our piece on concierge men's health after 35. The goal is to match the treatment to the biology, not to the most convenient protocol.

When clomiphene is not the right answer

Honesty matters here. Clomiphene is not universally better than TRT, and framing it that way would be wrong.

For men with primary hypogonadism, it does not work. For men with very low testosterone who need a reliable and rapid response, TRT tends to be more predictable. For men over 50 with diminished testicular reserve, the response to clomiphene may be modest even if the axis is technically intact. For men who have tried clomiphene at appropriate doses for 3 months without meaningful lab or symptom improvement, continuing is not justified.

There is also a practical consideration around monitoring. Clomiphene requires the same lab follow-up as TRT -- it is not a set-it-and-forget-it prescription. Men who are not going to follow up consistently are better served by a protocol that can be monitored reliably.

What we can offer is a real evaluation that tells you which category you are in, explains the tradeoffs honestly, and makes a recommendation we can defend on paper.

Your next step

If your testosterone has been flagged as low -- or if you have symptoms that make you wonder -- the most useful thing you can do is get a proper workup before you commit to any treatment. That means two morning draws, the right panel of supporting labs, and a clinician who will look at the pattern before writing anything.

We do that at NoMi Beach Health. Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) leads the evaluation, the conversation is 45 minutes, and the answer you leave with is based on your biology -- not a template.

Visit our men's health services page to book a new-patient visit, or call us at (786) 744-5152. We will look at the labs, walk through the options, and tell you what we actually think.